Acceleron blood disease drug hits goal in pivotal clinical trial
Acceleron Pharma said Thursday that its experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the blood disease myelodysplastic syndrome, meeting the primary goal of a Phase 3 clinical trial.
Based on the study
